Lataa...
Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve
BACKGROUND: Two ongoing phase II clinical trials (RENEW and SYNERGY) have been developed to test the efficacy of anti-LINGO-1 antibodies in acute optic neuritis and relapsing forms of multiple sclerosis, respectively. Across a range of experimental models, LINGO-1 has been found to inhibit neuron an...
Tallennettuna:
| Julkaisussa: | Mult Scler J Exp Transl Clin |
|---|---|
| Päätekijät: | , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5433342/ https://ncbi.nlm.nih.gov/pubmed/28607723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217316641704 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|